UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 92

Sortiert nach

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

Biochemical journal, 2009-06, Vol.421 (1), p.29-42

2009

Link zum Volltext

Verfügbarkeit prüfen

MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion

Clinical cancer research, 2019-08, Vol.25 (16), p.5107-5121

2019

Link zum Volltext

Verfügbarkeit prüfen

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer

Molecular cancer therapeutics, 2018-05, Vol.17 (5), p.908-920

2018

Link zum Volltext

Verfügbarkeit prüfen

Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells

Science signaling, 2013-03, Vol.6 (268), p.rs6

2013

Link zum Volltext

Verfügbarkeit prüfen

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Molecular cancer therapeutics, 2015-11, Vol.14 (11), p.2508-2518

2015

Link zum Volltext

Verfügbarkeit prüfen

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

Breast cancer research : BCR, 2019-12, Vol.21 (1), p.135-135, Article 135

2019

Link zum Volltext

Verfügbarkeit prüfen

AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival

Clinical cancer research, 2019-03, Vol.25 (5), p.1574-1587

2019

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

Breast cancer research : BCR, 2020-01, Vol.22 (1), p.14-14, Article 14

2020

Link zum Volltext

Verfügbarkeit prüfen

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Molecular cancer therapeutics, 2016-05, Vol.15 (5), p.877-889

2016

Link zum Volltext

Verfügbarkeit prüfen

Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT

Journal of medicinal chemistry, 2012-02, Vol.55 (3), p.1261-1273

2012

Link zum Volltext

Verfügbarkeit prüfen

Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity

Oncoimmunology, 2018-01, Vol.7 (8), p.e1458810-e1458810

2018

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models

Oncotarget, 2017-12, Vol.8 (69), p.113874-113884

2017

Link zum Volltext

Verfügbarkeit prüfen

Novel Role for p110β PI 3-Kinase in Male Fertility through Regulation of Androgen Receptor Activity in Sertoli Cells

PLoS genetics, 2015-07, Vol.11 (7), p.e1005304-e1005304

2015

Link zum Volltext

Verfügbarkeit prüfen

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers

Oncotarget, 2016-07, Vol.7 (30), p.48206-48219

2016

Link zum Volltext

Verfügbarkeit prüfen

Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines

PloS one, 2013-10, Vol.8 (10), p.e75045-e75045

2013

Link zum Volltext

Verfügbarkeit prüfen

How is the acyl chain composition of phosphoinositides created and does it matter?

Biochemical Society transactions, 2019-10, Vol.47 (5), p.1291-1305

2019

Link zum Volltext

Verfügbarkeit prüfen

Genome-Wide Estrogen Receptor Activity in Breast Cancer

Endocrinology (Philadelphia), 2021-02, Vol.162 (2), p.1

2021

Link zum Volltext

Verfügbarkeit prüfen

Bcl-2 regulates a caspase-3/caspase-2 apoptotic cascade in cytosolic extracts

Oncogene, 1999-03, Vol.18 (10), p.1781-1787

1999

Link zum Volltext

Verfügbarkeit prüfen

Regulation of apoptosis by BH3 domains in a cell-free system

Current biology, 1997-12, Vol.7 (12), p.913-920

1997

Link zum Volltext

Verfügbarkeit prüfen

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

Nature (London), 2016-06, Vol.534 (7606), p.272-276

2016

Link zum Volltext

Verfügbarkeit prüfen

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper

Clinical cancer research, 2022-11, Vol.28 (21), p.4724-4736

2022

Link zum Volltext

Verfügbarkeit prüfen

Acyl chain selection couples the consumption and synthesis of phosphoinositides

The EMBO journal, 2022-09, Vol.41 (18), p.e110038-n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K

Molecular cell, 2017-11, Vol.68 (3), p.566-580.e10

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(88)

Publikationsform

Artikel
(91)
Dissertationen
(1)

Sprache

Englisch
(92)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(49)
Life Sciences & Biomedicine
(46)
Humans
(38)
Animals
(34)
Oncology
(20)
Cell Line, Tumor
(18)
Mice
(18)
Biochemistry & Molecular Biology
(14)
Cell Biology
(14)
Female
(13)
Xenograft Model Antitumor Assays
(12)
Male
(10)
Chemistry, Medicinal
(9)
Pharmacology & Pharmacy
(9)
Rats
(9)
Antineoplastic Agents - Pharmacology
(8)
Biological And Medical Sciences
(8)
Cell Proliferation - Drug Effects
(8)
Protein Kinase Inhibitors - Pharmacology
(8)
Chemistry
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(20)
Journal Of Medicinal Chemistry
(10)
Molecular Cancer Therapeutics
(10)
Bioorganic & Medicinal Chemistry Letters
(7)
Clinical Cancer Research
(5)
Current Biology
(4)
Hepatology
(4)
Carcinogenesis
(3)
Molecular Cell
(3)
Plos Genetics
(3)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer

Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS -Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT

Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity

Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models

Novel Role for p110β PI 3-Kinase in Male Fertility through Regulation of Androgen Receptor Activity in Sertoli Cells

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers

Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines

How is the acyl chain composition of phosphoinositides created and does it matter?

Genome-Wide Estrogen Receptor Activity in Breast Cancer

Bcl-2 regulates a caspase-3/caspase-2 apoptotic cascade in cytosolic extracts

Regulation of apoptosis by BH3 domains in a cell-free system

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper

Acyl chain selection couples the consumption and synthesis of phosphoinositides

PTEN Regulates PI(3,4)P 2 Signaling Downstream of Class I PI3K

PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K

Suchergebnisse filtern